The Latest Cardiac and Vascular News
Significant Opportunity Seen as Patient Visits Resume to Emphasize VASCEPA as the First and Only Drug Approved for Its Current Cardiovascular Risk Reduction Indication DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today announced […]
DUBLIN, Ireland and BRIDGEWATER, N.J., May 21, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA®) on inflammatory biomarkers and other patient outcomes in individuals with […]
First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses Results of prespecified tertiary endpoint analyses consistent across different types of coronary revascularization procedures, including urgent, emergent, and elective interventions […]
Total Revenue Increased 112% to $155 Million in First Quarter 2020 Compared to Prior Year Management to Host Conference Call at 7:30 a.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., April 30, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today […]
Serum EPA Levels Showed Approximately 400% Increase Following Administration of VASCEPA High EPA Levels Associated with Substantial Reductions in Multiple Cardiovascular Endpoints Including Heart Failure and Total Mortality Amarin to Webcast Discussion of Presented Data March 30, 5:30 – 6:30 […]
Record Revenue of $429.8 Million and $143.3 Million for Full Year and Fourth Quarter 2019 Launch Commenced of VASCEPA® as First and Only Drug with Its New Cardiovascular Risk Reduction Indication Management to Host Conference Call at 4:30 p.m. ET Today DUBLIN, […]
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), announced today that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication for VASCEPA® (icosapent ethyl) by the […]
Unaudited Full-Year 2019 Net Total Revenue Estimated At or Slightly Above Upper-End of Prior Guidance of $410 to $425 Million U.S. Sales Force Expansion On-Track for Doubling to 800 Sales Professionals in Early 2020 Full-Year 2020 Net Total Revenue Guidance […]
VASCEPA becomes the first and only Health Canada approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in the studied high-risk patients approved for treatment Commercial launch expected in mid-February 2020 by Amarin’s commercial partner for Canada VASCEPA approval was […]
REDUCE-IT USA results, in prespecified subgroup analyses, showed cardiovascular risk reductions across all endpoints, including 30% relative risk reduction in all-cause mortality New analysis determined icosapent ethyl (Vascepa®) is highly cost-effective in patients from the REDUCE-IT study and, as is rarely […]
